Cargando…
Prognostic value of HLA class I expression in patients with colorectal cancer
BACKGROUND: Prognostic factors are useful for determination of the therapeutic strategy and follow-up examination after curative operation in cancer treatment. The immunological state of the host can influence the prognosis for cancer patients as well as the features of the cancer. Human lymphocyte...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336735/ https://www.ncbi.nlm.nih.gov/pubmed/25889416 http://dx.doi.org/10.1186/s12957-015-0456-2 |
_version_ | 1782358510257831936 |
---|---|
author | Iwayama, Yuji Tsuruma, Tetsuhiro Mizuguchi, Toru Furuhata, Tomohisa Toyota, Nobuhiko Matsumura, Masayuki Torigoe, Toshihiko Sato, Noriyuki Hirata, Koichi |
author_facet | Iwayama, Yuji Tsuruma, Tetsuhiro Mizuguchi, Toru Furuhata, Tomohisa Toyota, Nobuhiko Matsumura, Masayuki Torigoe, Toshihiko Sato, Noriyuki Hirata, Koichi |
author_sort | Iwayama, Yuji |
collection | PubMed |
description | BACKGROUND: Prognostic factors are useful for determination of the therapeutic strategy and follow-up examination after curative operation in cancer treatment. The immunological state of the host can influence the prognosis for cancer patients as well as the features of the cancer. Human lymphocyte antigen (HLA) class I molecules have a central role in the anti-cancer immune system. Therefore, we focused on the HLA class I expression level in cancer cells to investigate its prognostic value in patients with colorectal cancer. METHODS: We reviewed the clinical pathology archives of 97 consecutive patients with stage II colorectal cancer who underwent curative operation at the Sapporo Medical University, Japan, from February 1994 to January 2005. Fifty-six high-risk patients had adjuvant chemotherapy. The cancer cell membrane immunoreactivity level for HLA class I expressed by EMR8-5 was classified into three categories (positive, dull, and negative). In this study, the cases were divided into two groups: “positive” and “dull/negative”. HLA class I expression level and clinicopathological parameters were evaluated with the Pearson χ(2) test. Survival analysis was assessed by the Kaplan-Meier methods, and the differences between survival curves were analyzed using the log-rank test. RESULTS: Immunohistochemical study of HLA class I revealed the following. There were 51 cases that were positive, 40 were dull, and six negative. The HLA class I expression level had no significant correlation with other clinicopathological parameters, except for gender. Univariate and multivariate analyses related to disease-free survival (DFS) revealed that tumor location, HLA expression level, and venous invasion were significant independent prognostic factors (P < 0.05). The 5-year DFS rates in HLA class I positive group and in the dull/negative group were 89% and 70%, respectively. For high-risk patients with adjuvant chemotherapy, the 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 84% and 68%, respectively. For low-risk patients without the chemotherapy, the 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 100% and 71%, respectively. CONCLUSIONS: Our study concluded that the HLA class I expression level might be a very sensitive prognostic factor in colorectal cancer patients with stage II disease. |
format | Online Article Text |
id | pubmed-4336735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43367352015-02-23 Prognostic value of HLA class I expression in patients with colorectal cancer Iwayama, Yuji Tsuruma, Tetsuhiro Mizuguchi, Toru Furuhata, Tomohisa Toyota, Nobuhiko Matsumura, Masayuki Torigoe, Toshihiko Sato, Noriyuki Hirata, Koichi World J Surg Oncol Research BACKGROUND: Prognostic factors are useful for determination of the therapeutic strategy and follow-up examination after curative operation in cancer treatment. The immunological state of the host can influence the prognosis for cancer patients as well as the features of the cancer. Human lymphocyte antigen (HLA) class I molecules have a central role in the anti-cancer immune system. Therefore, we focused on the HLA class I expression level in cancer cells to investigate its prognostic value in patients with colorectal cancer. METHODS: We reviewed the clinical pathology archives of 97 consecutive patients with stage II colorectal cancer who underwent curative operation at the Sapporo Medical University, Japan, from February 1994 to January 2005. Fifty-six high-risk patients had adjuvant chemotherapy. The cancer cell membrane immunoreactivity level for HLA class I expressed by EMR8-5 was classified into three categories (positive, dull, and negative). In this study, the cases were divided into two groups: “positive” and “dull/negative”. HLA class I expression level and clinicopathological parameters were evaluated with the Pearson χ(2) test. Survival analysis was assessed by the Kaplan-Meier methods, and the differences between survival curves were analyzed using the log-rank test. RESULTS: Immunohistochemical study of HLA class I revealed the following. There were 51 cases that were positive, 40 were dull, and six negative. The HLA class I expression level had no significant correlation with other clinicopathological parameters, except for gender. Univariate and multivariate analyses related to disease-free survival (DFS) revealed that tumor location, HLA expression level, and venous invasion were significant independent prognostic factors (P < 0.05). The 5-year DFS rates in HLA class I positive group and in the dull/negative group were 89% and 70%, respectively. For high-risk patients with adjuvant chemotherapy, the 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 84% and 68%, respectively. For low-risk patients without the chemotherapy, the 5-year DFS rates in the HLA class I positive group and in the dull/negative group were 100% and 71%, respectively. CONCLUSIONS: Our study concluded that the HLA class I expression level might be a very sensitive prognostic factor in colorectal cancer patients with stage II disease. BioMed Central 2015-02-12 /pmc/articles/PMC4336735/ /pubmed/25889416 http://dx.doi.org/10.1186/s12957-015-0456-2 Text en © Iwayama et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Iwayama, Yuji Tsuruma, Tetsuhiro Mizuguchi, Toru Furuhata, Tomohisa Toyota, Nobuhiko Matsumura, Masayuki Torigoe, Toshihiko Sato, Noriyuki Hirata, Koichi Prognostic value of HLA class I expression in patients with colorectal cancer |
title | Prognostic value of HLA class I expression in patients with colorectal cancer |
title_full | Prognostic value of HLA class I expression in patients with colorectal cancer |
title_fullStr | Prognostic value of HLA class I expression in patients with colorectal cancer |
title_full_unstemmed | Prognostic value of HLA class I expression in patients with colorectal cancer |
title_short | Prognostic value of HLA class I expression in patients with colorectal cancer |
title_sort | prognostic value of hla class i expression in patients with colorectal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336735/ https://www.ncbi.nlm.nih.gov/pubmed/25889416 http://dx.doi.org/10.1186/s12957-015-0456-2 |
work_keys_str_mv | AT iwayamayuji prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT tsurumatetsuhiro prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT mizuguchitoru prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT furuhatatomohisa prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT toyotanobuhiko prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT matsumuramasayuki prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT torigoetoshihiko prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT satonoriyuki prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer AT hiratakoichi prognosticvalueofhlaclassiexpressioninpatientswithcolorectalcancer |